Eplerenone – the pillar of heart failure therapy Review article
Article Sidebar
Published:
Jun 30, 2024
Keywords:
heart failure, eplerenone, therapy optimization
Main Article Content
Abstract
Heart failure is the main cause of death both in Poland and worldwide. Moreover, numerous rehospitalizations of patients with heart failure place a very heavy financial burden on health care systems. The guidelines of the European Society of Cardiology provide detailed recommendations for the treatment of patients with heart failure, including treatment schemes with specific molecules. Moreover, more and more attention is paid to prescribing optimal doses of the recommended drugs. The latest published data confirm the relevance of using higher doses used in the heart failure treatment schemes.
Article Details
How to Cite
Krzowski, B., & Grabowski, M. (2024). Eplerenone – the pillar of heart failure therapy. Medycyna Faktow (J EBM), 17(2(63), 263-266. https://doi.org/10.24292/01.MF.0224.13
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Kałużna-Oleksy M (red.). Niewydolność Serca w Polsce – realia, koszty, sugestie poprawy sytuacji. 2020.
2. Zdrojewski T, Rutkowski M, Bandosz P et al. Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiol Pol. 2013; 71(4): 381-92.
3. Niklas A, Marcinkowska J, Kozela M et al. Prevalence of cardiometabolic risk factors and selected cardiovascular diseases in hypertensive and normotensive participants in the adult Polish population: The WOBASZ II study. Medicine (Baltimore). 2020; 99(28): e21149.
4. Wojtyniak B, Gierlotka M, Opolski G et al. Observed and relative survival and 5-year outcomes of patients discharged after acute myocardial infarction: the nationwide AMI-PL database. Kardiol Pol. 2020; 78(10): 990-8.
5. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599-726.
6. Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1): 11-21.
7. Nessler J, Krawczyk K, Leszek P et al. Opinia ekspertów Asocjacji Niewydolności Serca Polskiego Towarzystwa Kardiologicznego, Kolegium Lekarzy Rodzinnych w Polsce oraz Polskiego Towarzystwa Medycyny Rodzinnej dotycząca postępowania w okresie okołowypisowym u pacjentów z niewydolnością serca. Polish Heart Journal (Kardiologia Polska). 2022; 80(II): 34-56.
8. Mebazaa A, Davison B, Chioncel O et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022; 400(10367): 1938-52.
9. Piotrowicz E, Pencina MJ, Opolski G et al. Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure: The Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomized Clinical Trial. JAMA Cardiol. 2020; 5(3): 300-8.
2. Zdrojewski T, Rutkowski M, Bandosz P et al. Prevalence and control of cardiovascular risk factors in Poland. Assumptions and objectives of the NATPOL 2011 Survey. Kardiol Pol. 2013; 71(4): 381-92.
3. Niklas A, Marcinkowska J, Kozela M et al. Prevalence of cardiometabolic risk factors and selected cardiovascular diseases in hypertensive and normotensive participants in the adult Polish population: The WOBASZ II study. Medicine (Baltimore). 2020; 99(28): e21149.
4. Wojtyniak B, Gierlotka M, Opolski G et al. Observed and relative survival and 5-year outcomes of patients discharged after acute myocardial infarction: the nationwide AMI-PL database. Kardiol Pol. 2020; 78(10): 990-8.
5. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599-726.
6. Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1): 11-21.
7. Nessler J, Krawczyk K, Leszek P et al. Opinia ekspertów Asocjacji Niewydolności Serca Polskiego Towarzystwa Kardiologicznego, Kolegium Lekarzy Rodzinnych w Polsce oraz Polskiego Towarzystwa Medycyny Rodzinnej dotycząca postępowania w okresie okołowypisowym u pacjentów z niewydolnością serca. Polish Heart Journal (Kardiologia Polska). 2022; 80(II): 34-56.
8. Mebazaa A, Davison B, Chioncel O et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022; 400(10367): 1938-52.
9. Piotrowicz E, Pencina MJ, Opolski G et al. Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure: The Telerehabilitation in Heart Failure Patients (TELEREH-HF) Randomized Clinical Trial. JAMA Cardiol. 2020; 5(3): 300-8.